Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Probably right.
How's bidness? Still do work in the industry?
Almost all my friends have sold out to larger better capitalized companies except one here in Denver.
For better or worse, corporate cannabis has taken over yet the storefront names have not all changed. Great for the average consumer who are happy with standardized mid-grade bud, but sucks for those who seek easy access to the superfine.
Small high quality growers and shops will have their day in the sun in due time. A craft brewer phenomena will happen in the cannabis space after federal tax and banking changes.
So the 70% insider ownership you state is an OPINION. LOL!
Since I work with facts from free PRIMARY sources like the SEC, I have no problem showing my work.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1451512/000162828022009362/trtc-20211231.htm#ifbe1f820ba484696aab835afcc20e4b3_91
In the real world:
Show your work then and prove the SEC filing wrong. Your spreadsheet is poo poo.
Thus far among probably many errors you are incorrectly assuming unexercised options are ownership, among probably many other imaginary maths to come up with your 70% insider ownership.
The 10-K filed with the SEC is accurate, the 70% insider ownership you stated is incorrect.
Facts are facts.
How about "fundamentals", believe in those?
The only value in $UNRV is in volatile trading potential and that requires technical analysis of factors such as resistance.
This statement is true as I made my first million on $GWPH (GW Pharma acquired by $JAZZ) by thinking differently.
There is NOTHING unique or special between $UNRV and the many, many, small pot shops facing similar low revenue growth and high expenses.
There may be a trade in $UNRV, but as I've stated since the $TRTC days there is NO fundamental investment value even with the long overdue passage of safe banking and/or rescheduling.
Not true... only 25% is owned by insiders and this was mostly due to the 100% dilution experienced in the merger to create Unrivaled.
False statement, facts below: "70% of stock is owned by insiders. every penny in stock price should matter to them."
Lost cause is my answer.
$UNRV is too small, too inefficient, has too much competition, and a lack of affordable financing to truly take advantage of the long overdue tax and banking changes.
No, to the contrary. I thought Anavex was relating it's broad S1R portfolio to another top of mind indication, Covid.
Also, there has been a recent influx of articles analyzing patterns of dementia and Covid. So I took it as a positive.
As I've said many times, by many financial metrics, the common equity of $UNRV and $TRTC before it is worthless, and only recently has the market adjusted to the reality of the situation.
The standard OTC playbook requires more of the same:
No, it will be another reverse split and/or merger with anyone willing to pony up cash.
Existing shares are worth sub-pennies upon the current pennies of value.
Exactly why I'm in $AVXL for the upstream MOA.
Unfortunately politics and money have made the FDA so biased to approve amyloid drugs it's resulted in a ridiculously low bar for approval.....with no need for clinical efficacy?!?
It must be part of the USA's race toward mediocrity.
"Cognitive Reserve" definitely makes evaluations difficult and is a very key concept to factor in. Trial design can mitigate it.
I'm coming from the Lewy Body Dementia angle on this. For those interested in this concept I recommend the documentary of Robin Williams, "Robin's Wish".
Good points. The devil is in the details, but at the moment it makes for good headlines.
Switching gears a bit to Parkinson's disease, this venue could be a good place to announce initiation "... of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial " October 13, 2022.
Especially since the MJFF has already agreed to pay for it.
https://www.michaeljfox.org/2022-pd-therapeutics-conference
My thoughts exactly, this is a very exciting time for new investors to discover $AVXL.
$AVXL seems to have had at least 2, maybe 3 "late braking" submissions since I started following in 2015.
"Late breaking abstract of cognitive outcome measures relevant to Alzheimer’s disease selected for oral presentation at CTAD"
https://www.anavex.com/post/anavex-life-sciences-presents-proof-of-concept-controlled-phase-2-clinical-trial-data
The estimate of $AVXL volume attributed the $XBI was way off.
That was the cabal portion of the volume...
So incorrect it's sad.
The early day "boots on the ground" DD was legit. I do think his name was Dennis too btw. I think he did landscaping.
Anybody can sell worthless paper on the OTC, so that was actually helpful at the time. The OTC is not a market I frequent unless foreign ordinary or ADR's. Cannabis was an exception and still is.
Until the fricking government allows full banking, it's a tough gig.
Also, Peterson and his buddies from the industry made huge amounts on money off of the toxic discounted equity convertible debt financing. With "free money" flowing from retail, management had ZERO incentive to try to operate the business efficiently. It was too good of an opportunity to pass up for an ex-junk bond salesman (Peterson) to not engage in self enrichment at retail investor and vendors expense.
Many of us rode the pump and bailed before the dump. I was so incredibly hated by the $TRTC pumpers it was rewarding to have called $TRTC demise.
I heard many stories from vendors of financial mismanagement that was probably fraud at best, theft at worst. Sad thing is I think the practice was rampant.
I can't say I'm a fan of "corporate cannabis" and the glut of mid-grade on the market and ultra fine cannabis hard to find, but they do run a legitimate business even within the cash model.
Heck it'd be nice if $UNRV could drum up enough support for simply a moderator on this forum.
Compliance approved....
$AVXL is a We Got This (WGT) stock until the science fails a trial.
$AVXL is becoming a classic binary event biotech play, and the sane back up plan for most investors should be to brace for 100% loss of the investment. Thus the $AVXL allocation should be based on individualized client parameters and suitability.
^^^^ that's my compliance approved version for financial advisor types.
But...my no longer registered advice is follow the trail of evidence regarding the growing confirmatory emerging science of S1R and muscarinic modulation and bet for success.
"Gotta be in it to win it", "Once in a lifetime opportunity" and other cliches apply to those comfortable with the risks.
Today's trading basically tells me retail isn't quite as "tapped out" as I had thought. They remain quite excitable, almost back to MEME levels for short periods.
I find that quite encouraging for speculative equity in general.
The stench of Remi's lack of ethics back in the Pain Therapeutics days has me completely biased against him and by extension to $SAVA.
IMO, $AVXL has been a quiet hard working company frugally putting together data for a potential paradigm change in the treatment of AD, PD/PDD and all Sigma 1R responsive indications.
I agree with you, Dr. M is a conservative type in his style of management and I'm guessing also in his private finances. I can respect that.
On the other hand, Remi and crew are biotech salesman types and loudmouths, an I suspect are more loyal to the investment banks than retail shareholders. A 100K smoke show sure generated a lot of volume... Just my opinion of course.
"it substantially eliminated the $AVXL millionaires club." As did the recent drop in all the equity markets... so it's all relative.
On a side note, the wicked fast rebound on the major equity markets has definitely caught people wrong footed.
Institutions have been selling $SAVA...not buying... do some research.
Institutional Shares (Long) 10,553,387 (ex 13D/G) - change of -1.32MM shares -11.12% MRQ
https://fintel.io/so/us/sava
At the marco level sure, but this is a stock board, so my observations are at the dispensary and vertical integrated firm level. Thus far and currently the industry revenue growth is spread out among many unprofitable firms of which $UNRV is one of many.
Consolidation is starting to fix that and improve the economies of scale and spread out the SG&A and compliance costs.
Keep the faith brotha, someday ya'll will turn a profit on the revenue... or not.
I'll be interested in the comparables as it appears cannabis is no longer a "growth" industry on the dispensary level.
Agree, he best get out the lipstick as my guess is the comparables will be ugly. Such a shitty time to be a dispensary operator and I don't see much on the horizon to change that. Especially California.
Will this be a full 4 quarters of post "merger" data?
blarcamesine, the best of the bunch firetruck.
Made me chuckle, good summary.
The incompetence continues ... but hey they hired another "interim" CEO.
FORM 12b-25
NOTIFICATION OF LATE FILING
https://www.sec.gov/Archives/edgar/data/0001451512/000147793222006139/unrv_nt10q.htm
LOL..or like a new Prevagen.
Your comment reminded me of that bryostatin stuff, whatever happened to that compound? I think from Neurotrope, then Synatogenix.
General question, btw, not direct to you gator. ;) unless you remember that story.
Very exciting stuff on the Rett front, how it's all filed with the FDA is still up for debate. We've learned how trial parameters are definitely important, as shown in the measurement debates with RQBQ-AUC versus change from baseline.
On the rare disease front in general, trials should be starting soon. Oh and the "mystery indication"...
Anavex has ran as large of trials as they had funding for. There was no "messing up", and only since the 2021 capital raise has $AVXL had a decent cash balance to run larger trials.
Also, regarding Rett, "I think he finally realised that he needs larger cohorts and this is the true reason behind expanding the Excellence trial." I doubt Dr.M "finally realized" anything...it's the public that are the ones finally understanding what has been done and why.
"The two upcoming readouts will be the endgame for 2-73 IMO." ... yes very much some put up or shut up moments ahead.
Truth bombs with high effect on target!
"We may approach 100M by the time we secure a partner and/or have an approved pathway. Need to give TGD credit on this!!"
I agree!
The other issue is scientific integrity and time wasted.
Just venting my frustration and looking forward to new MOA's such as S1R and muscarinic modulation.